CollPlant Biotechnologies (CLGN) Scheduled to Post Quarterly Earnings on Thursday

CollPlant Biotechnologies (NASDAQ:CLGNGet Free Report) is set to release its earnings data before the market opens on Thursday, April 4th. Analysts expect CollPlant Biotechnologies to post earnings of ($0.07) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

CollPlant Biotechnologies Stock Performance

NASDAQ:CLGN opened at $5.26 on Wednesday. CollPlant Biotechnologies has a 1 year low of $4.22 and a 1 year high of $8.90. The firm has a 50 day moving average of $5.32 and a 200-day moving average of $5.48. The stock has a market capitalization of $60.23 million, a P/E ratio of -8.62 and a beta of 0.24.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of CollPlant Biotechnologies by 53.9% in the first quarter. Bank of America Corp DE now owns 7,389 shares of the company’s stock valued at $52,000 after acquiring an additional 2,589 shares during the last quarter. Credit Suisse AG acquired a new stake in shares of CollPlant Biotechnologies in the fourth quarter valued at approximately $51,000. Jane Street Group LLC acquired a new stake in shares of CollPlant Biotechnologies in the third quarter valued at approximately $90,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of CollPlant Biotechnologies in the second quarter valued at approximately $189,000. Finally, LPL Financial LLC acquired a new stake in shares of CollPlant Biotechnologies in the second quarter valued at approximately $361,000. Institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

(Get Free Report)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.

Further Reading

Earnings History for CollPlant Biotechnologies (NASDAQ:CLGN)

Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.